Ji Heon Chae

Ms. Ji Heon Chae

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Sensors
Verified
Journal Article
Open access
PDF file
JLjiang fang lin
jiang fang lin
STSAIZHAO TANG
SAIZHAO TANG
SESeonho Eom
Seonho Eom
JLJae-Young Lee
Jae-Young Lee
JCJi Heon Chae
Ji Heon Chae
CKChul-Hyun Kim
Chul-Hyun Kim
Purpose: This study aimed to verify whether bioelectrical impedance vector analysis (BIVA) can support the clinical evaluation of sarcopenia in elderly individuals and evaluate the relationships between phase angle (PhA), physical performance, and muscle mass. Methods: The sample comprised 134 free-living elderly individuals of both sexes aged 69–91 years. Anthropometric parameters, grip strength, dual-energy X-ray absorptiometry findings, bioimpedance analysis results, and physical performance were also measured. The impedance vector distributions were evaluated in elderly individuals using BIVA. Results: BIVA revealed significant differences between the sarcopenia and non-sarcopenia groups (both sexes). The sarcopenia group had a significantly lower PhA than the non-sarcopenia group in both sexes (p < 0.05). PhA was significantly correlated with age, appendicular skeletal muscle (ASM), handgrip strength (HGS), and muscle quality in both sexes and significantly correlated with ASM/Height2 and physical performance in males. Conclusion: BIVA can be used as a field assessment method in elderly Koreans with sarcopenia. PhA is a good indicator of muscle strength, muscle quality, and physical performance in males. These methods can help diagnose sarcopenia in elderly individuals with reduced mobility.

23 August 2024 in Genes
Verified
Journal Article
Open access
PDF file
JCJi Heon Chae
Ji Heon Chae
SESeonho Eom
Seonho Eom
SLSang-Ki Lee
Sang-Ki Lee
JJJoo-Ha Jung
Joo-Ha Jung
CKChul-Hyun Kim
Chul-Hyun Kim
ACTN3 R577X and ACE I/D polymorphisms are associated with endurance exercise ability. This case–control study explored the association of ACTN3 and ACE gene polymorphisms with elite pure endurance in Korean athletes, hypothesizing that individuals with both ACTN3 XX and ACE II genotypes would exhibit superior endurance. We recruited 934 elite athletes (713 males, 221 females) and selected 45 pure endurance athletes (36 males, 9 females) requiring “≥90% aerobic energy metabolism during sports events”, in addition to 679 healthy non-athlete Koreans (361 males, 318 females) as controls. Genomic DNA was extracted and genotyped for ACTN3 R577X and ACE I/D polymorphisms. ACE ID (p = 0.090) and ACTN3 RX+XX (p = 0.029) genotype distributions were significantly different between the two groups. Complex ACTN3-ACE genotypes also exhibited significant differences (p = 0.014), with dominant complex genotypes positively affecting endurance (p = 0.039). The presence of RX+II or XX+II was associated with a 1.763-fold higher likelihood of possessing a superior endurance capacity than that seen in healthy controls (90% CI = 1.037–3.089). Our findings propose an association of combined ACTN3 RX+XX and ACE II genotypes with enhanced endurance performance in elite Korean athletes. While causality remains to be confirmed, our study highlights the potential of ACTN3-ACE polymorphisms in predicting elite endurance.

25 June 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
STSAIZHAO TANG
SAIZHAO TANG
JLjiang fang lin
jiang fang lin
SESeonho Eom
Seonho Eom
JLJae-Young Lee
Jae-Young Lee
JCJi Heon Chae
Ji Heon Chae
CKChul-Hyun Kim
Chul-Hyun Kim
Sarcopenia becomes more common with age, being most prevalent among elderly individuals. According to the EWGSOP, muscle mass is one of the criteria for the evaluation of sarcopenia. The main methods for evaluating muscle mass are CT, MRI, and DXA, but these methods are difficult to apply in the field due to equipment costs, radioactivity, and lack of portability. BIVA and PhA are alternative approaches for assessing somatic cell mass and volume and do not require predictive equations. These variables are clinically relevant parameters that indicate cell health, especially cell membrane integrity and cell function. This study in sarcopenic and nonsarcopenic elderly volunteers aimed to determine the BIVA distribution pattern among individual sarcopenia patients; to evaluate the relationship between PhA and muscle strength, muscle quality, and physical function; and to find any correlates of PhA. The sample comprised 134 free-living elderly individuals of both sexes aged 69–91 years. Anthropometric parameters, grip strength, DXA findings, BIA results, and physical performance (the 6-meter walk test) were measured. Impedance vector distributions were evaluated in sarcopenia patients and healthy elderly individuals using BIVA. According to the AWGS criteria, sarcopenia was diagnosed according to DXA findings, grip strength and physical performance test results. Group differences were evaluated using the t test, Mann‒Whitney U test, and Hotelling's T2 test. Correlation analysis was performed to identify variables significantly associated with PhA. Linear regression analysis was performed to determine whether PhA was associated with muscle strength, muscle quality and physical function. BIVA detected a significant difference between the sarcopenia and non-sarcopenia groups (both sexes) due to higher R/H values and lower phase angles in a few individuals, whereas Xc/Ht values did not differ between the two groups. The sarcopenia group had a significantly lower PhA than the non-sarcopenia group among both males (p<0.01) and females (p<0.05). PhA was significantly correlated with age, ASM, HGS, and muscle quality in both sexes and significantly correlated with ASM/Ht2 and physical performance in males. PhA was a significant indicator of muscle strength in both males (β = 2.6; p<0.01) and females (β = 3.4; p<0.01), a significant indicator of muscle quality in both males (β = 0.07; p<0.05) and females (β = 0.17; p<0.01), and a significant indicator of physical performance in males (β = 0.3; p<0.01). BIVA can detect changes in muscle mass in individuals with sarcopenia and is a practical method for the assessment of sarcopenia in the field. PhA is a good indicator of muscle strength, muscle quality and physical performance (in males). These methods can help diagnose sarcopenia in elderly individuals with reduced mobility.

3 July 2026 in International Journal of Obesity
Verified
Journal Article
Open access
HKHeeyeon Kim
Heeyeon Kim
JCJi Heon Chae
Ji Heon Chae
HMHyo Youl Moon
Hyo Youl Moon
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective pharmacological treatments for obesity, through appetite suppression and weight reduction. However, their potential influence on physical activity (PA), a key determinant of long-term energy balance, remains unclear. This review aimed to evaluate whether GLP-1 RA treatment affects objectively measured PA in adults with overweight or obesity. A systematic review and exploratory meta-analysis were conducted in accordance with PRISMA guidelines. PubMed and Embase were searched from inception to March 10, 2026. Eligible studies included randomized and non-randomized controlled trials examining objectively measured PA outcomes (e.g., step counts, sedentary time, and intensity-specific PA). Narrative synthesis was performed across all studies, and a random-effects meta-analysis was conducted for studies reporting comparable free-living PA outcomes. Seven studies from six independent trials ( n = 924) were included. Most studies reported no statistically significant differences in PA between GLP-1 RA and control groups. However, five studies (71.4%) showed numerically lower free-living PA in GLP-1 RA-treated groups, with one study reporting a significant reduction in daily step counts (–1144 steps/day, p = 0.01). Structured exercise-related outcomes, including adherence and prescribed exercise duration, were comparable between groups. Meta-analysis of three RCTs showed no significant pooled effect (Hedges’ g = –0.11, 95% CI –0.30 to 0.09, I 2 = 0.0%). Sensitivity analyses suggested a modest reduction in PA (Hedges’ g = –0.24, 95% CI –0.46 to –0.02, p = 0.035, I 2 = 34.3%), influenced by study design and outcome heterogeneity. GLP-1 RA treatment does not significantly alter overall PA but may be associated with a small reduction in free-living PA, while structured exercise participation remains unaffected. These findings suggest a potential influence on spontaneous, non-obligatory activity rather than exercise capacity. Further studies using standardized objective PA measures are needed.